search
Back to results

Outcomes Following Vaginal Prolapse Repair and Mid Urethral Sling Trial (OPUS)

Primary Purpose

Pelvic Organ Prolapse

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
TVT
Sham
Sponsored by
NICHD Pelvic Floor Disorders Network
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pelvic Organ Prolapse focused on measuring Prolapse, Urinary incontinence, TVT

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

Vaginal bulge symptoms as indicated by an affirmative response to either questions 4 or 5 of the PFDI:

  • Do you usually have a sensation of bulging or protrusion from the vaginal area?
  • Do you usually have a bulge or something falling out that you can see or feel in the vaginal area? Anterior vaginal prolapse defined by pelvic organ prolapse quantification (POP-Q) Point Aa ≥ -1 cm (i.e., -1,0,1,2, or 3 cm).

Surgical plan that includes a vaginal approach for apical or anterior prolapse repair.

Able and willing to complete data collection per protocol, including written informed consent.

Exclusion Criteria:

Pregnancy or planning pregnancy in the first postoperative year. Any prior mid urethral sling. Currently participating in another interventional study for urinary incontinence.

Untreated urinary tract infection (may be included after resolution).

Overt symptoms of stress urinary incontinence as defined by a positive response to any of the following 3 PFDI items:

  • Do you usually experience urine leakage related to coughing, sneezing, or laughing?
  • Do you usually experience urine leakage related to physical exercise such as walking, running, aerobics, or tennis?
  • Do you usually experience urine leakage related to lifting or bending over? Currently being treated for stress urinary incontinence with pessary/incontinence ring, pelvic floor muscle exercise or medication (duloxetine and imipramine, and alpha agonists).

Sites / Locations

  • The University of Alabama at Birmingham
  • USCD Medical Center
  • Kaiser Permanente
  • Loyola University Medical Center
  • Duke University
  • Cleveland Clinic
  • UT Southwestern
  • University of Utah

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

1

2

Arm Description

Tension-free Vaginal Tape (TVT) surgery

Sham Tension-free Vaginal Tape (TVT) surgery

Outcomes

Primary Outcome Measures

Number of Participants With Treatment Failure Defined as Subsequent Treatment for Urinary Incontinence, Signs or Symptoms of Bothersome Urinary Incontinence
Defined as a positive cough stress test, bothersome incontinence symptoms, or treatment for urinary incontinence, and urinary incontinence (stress, urge, or mixed), regardless of whether interim treatment for incontinence had been provided.
Prevalence of Bothersome Urinary Incontinence at 12 Months Following Index Surgery
Defined as a positive cough stress test or report of bothersome incontinence symptoms.

Secondary Outcome Measures

Medical Outcomes Study 36-Item Short Form Health Survey
This survey is a generic health-related quality of life measure. Scores have normalized values with a mean of 50 and a standard deviation of 10, with higher scores indicating better health status. Results measure the average change in scores from baseline to follow-up.
Positive Cough Stress Test
A leakage of urine with coughing or straining in either the supine or standing position with the bladder filled through a urethral catheter to 300 ml.
Symptoms of Incontinence
Symptoms that were at least moderately bothersome to the participant (as measured by a response of "moderately" or "quite a bit" to any of the four items on the Pelvic Floor Distress Inventory regarding leakage).
Treatment for Incontinence
The need for treatment for any urinary incontinence, including surgery, medication, pessary for incontinence, supervised pelvic-muscle exercises, timed voiding and fluid management, periurethral injection, botulinum toxin injection, neuromodulation, or other treatment for incontinence.
Pelvic Floor Distress Inventory (PFDI) Urinary Distress Inventory (UDI)
PFDI is a symptom inventory for pelvic floor disorders. Scores ranges from 0 to 300, with higher scores indicating more symptoms. Results measure the average change in scores from baseline to follow-up.
Urinary Distress Inventory (UDI) Obstructive Symptom Subscale
Scores on the UDI subscales range from 0 to 100, with higher score indicating more symptoms. Results measure the average change in scores from baseline to follow-up.
Urinary Distress Inventory (UDI) Irritative Symptom Subscale
Scores on the UDI subscales range from 0 to 100, with higher score indicating more symptoms. Results measure the average change in scores from baseline to follow-up.
Urinary Distress Inventory (UDI) Stress Subscale
Scores on the UDI subscales range from 0 to 100, with higher score indicating more symptoms. Results measure the average change in scores from baseline to follow-up.
Incontinence Severity Index
Scores on the Incontinence Severity Index range from 1 to 12, with higher scores indicating greater severity. Results measure average change in scores from baseline.

Full Information

First Posted
April 13, 2007
Last Updated
April 30, 2018
Sponsor
NICHD Pelvic Floor Disorders Network
Collaborators
Office of Research on Women's Health (ORWH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT00460434
Brief Title
Outcomes Following Vaginal Prolapse Repair and Mid Urethral Sling Trial
Acronym
OPUS
Official Title
Outcomes Following Vaginal Prolapse Repair and Mid Urethral Sling (OPUS) Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
May 2007 (undefined)
Primary Completion Date
January 2011 (Actual)
Study Completion Date
March 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NICHD Pelvic Floor Disorders Network
Collaborators
Office of Research on Women's Health (ORWH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Pelvic organ prolapse is common among women with a prevalence that has been estimated to be as high as 30%. Prolapse may be corrected by surgery using either a vaginal or abdominal incision. Some women develop stress urinary incontinence (SUI) after surgery. A prior randomized trial has shown that use of a Burch sling at the time of an abdominal sacrocolpopexy decreases the risk of urinary incontinence; however, the benefit of adding an anti incontinence procedure to prevent SUI at the time of prolapse surgery performed via a vaginal approach is unclear. Thus, the objective of the Outcomes following vaginal Prolapse repair and mid Urethral Sling (OPUS) trial is to determine whether prophylactic treatment with Tension-free Vaginal Tape (TVT)® at the time of prolapse surgery done via a vaginal approach is effective in preventing urinary incontinence.
Detailed Description
The overall objective of this randomized clinical trial is to determine whether symptom-specific treatment of incontinence after prolapse surgery is equally effective to prophylactic treatment by adding TVT® at the time of the prolapse surgery among women with anterior vaginal prolapse but without pre-operative symptoms of stress urinary incontinence. The primary aims are: In stress continent women planning vaginal surgery for pelvic organ prolapse: To determine if the failure rate defined by subsequent treatment for urinary incontinence, signs or symptoms of bothersome urinary incontinence [defined as having at least moderate bother for any of 4 Pelvic Floor Distress Inventory (PFDI) incontinence items] differs between vaginal prolapse repair and vaginal prolapse repair plus TVT® during the first 3 months after the index surgery. To determine if the prevalence of bothersome urinary incontinence at 12 months after the index surgery differs between vaginal prolapse repair and vaginal prolapse repair plus TVT®, whether or not there was subsequent treatment for symptoms of urinary incontinence; i.e., to determine whether symptom-specific treatment of incontinence after prolapse surgery is equally effective to prophylactic treatment by adding a TVT® at the time of the prolapse surgery. To measure the total cost of care and relate the difference in cost of care between the two groups to differences in health utilities and health-related quality of life, which will allow us to examine the cost-effectiveness of prophylactic use of a TVT® at the time of prolapse surgery versus symptom-specific treatment of stress incontinence after prolapse surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pelvic Organ Prolapse
Keywords
Prolapse, Urinary incontinence, TVT

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
337 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Tension-free Vaginal Tape (TVT) surgery
Arm Title
2
Arm Type
Sham Comparator
Arm Description
Sham Tension-free Vaginal Tape (TVT) surgery
Intervention Type
Device
Intervention Name(s)
TVT
Intervention Description
Prophylactic TVT
Intervention Type
Other
Intervention Name(s)
Sham
Intervention Description
Sham TVT
Primary Outcome Measure Information:
Title
Number of Participants With Treatment Failure Defined as Subsequent Treatment for Urinary Incontinence, Signs or Symptoms of Bothersome Urinary Incontinence
Description
Defined as a positive cough stress test, bothersome incontinence symptoms, or treatment for urinary incontinence, and urinary incontinence (stress, urge, or mixed), regardless of whether interim treatment for incontinence had been provided.
Time Frame
3 months post-surgery
Title
Prevalence of Bothersome Urinary Incontinence at 12 Months Following Index Surgery
Description
Defined as a positive cough stress test or report of bothersome incontinence symptoms.
Time Frame
12 months post-surgery
Secondary Outcome Measure Information:
Title
Medical Outcomes Study 36-Item Short Form Health Survey
Description
This survey is a generic health-related quality of life measure. Scores have normalized values with a mean of 50 and a standard deviation of 10, with higher scores indicating better health status. Results measure the average change in scores from baseline to follow-up.
Time Frame
Baseline, 3 months, and 12 Months post-surgery
Title
Positive Cough Stress Test
Description
A leakage of urine with coughing or straining in either the supine or standing position with the bladder filled through a urethral catheter to 300 ml.
Time Frame
3 and 12 Months Post-surgery
Title
Symptoms of Incontinence
Description
Symptoms that were at least moderately bothersome to the participant (as measured by a response of "moderately" or "quite a bit" to any of the four items on the Pelvic Floor Distress Inventory regarding leakage).
Time Frame
3 and 12 Months Post-surgery
Title
Treatment for Incontinence
Description
The need for treatment for any urinary incontinence, including surgery, medication, pessary for incontinence, supervised pelvic-muscle exercises, timed voiding and fluid management, periurethral injection, botulinum toxin injection, neuromodulation, or other treatment for incontinence.
Time Frame
3 months post-surgery
Title
Pelvic Floor Distress Inventory (PFDI) Urinary Distress Inventory (UDI)
Description
PFDI is a symptom inventory for pelvic floor disorders. Scores ranges from 0 to 300, with higher scores indicating more symptoms. Results measure the average change in scores from baseline to follow-up.
Time Frame
Baseline, 3 months, and 12 months post-surgery
Title
Urinary Distress Inventory (UDI) Obstructive Symptom Subscale
Description
Scores on the UDI subscales range from 0 to 100, with higher score indicating more symptoms. Results measure the average change in scores from baseline to follow-up.
Time Frame
Baseline, 3 months, and 12 months post-surgery
Title
Urinary Distress Inventory (UDI) Irritative Symptom Subscale
Description
Scores on the UDI subscales range from 0 to 100, with higher score indicating more symptoms. Results measure the average change in scores from baseline to follow-up.
Time Frame
Baseline, 3 months, and 12 months post-surgery
Title
Urinary Distress Inventory (UDI) Stress Subscale
Description
Scores on the UDI subscales range from 0 to 100, with higher score indicating more symptoms. Results measure the average change in scores from baseline to follow-up.
Time Frame
Baseline, 3 months, and 12 months post-surgery
Title
Incontinence Severity Index
Description
Scores on the Incontinence Severity Index range from 1 to 12, with higher scores indicating greater severity. Results measure average change in scores from baseline.
Time Frame
Baseline, 3 months, and 12 months post-surgery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Vaginal bulge symptoms as indicated by an affirmative response to either questions 4 or 5 of the PFDI: Do you usually have a sensation of bulging or protrusion from the vaginal area? Do you usually have a bulge or something falling out that you can see or feel in the vaginal area? Anterior vaginal prolapse defined by pelvic organ prolapse quantification (POP-Q) Point Aa ≥ -1 cm (i.e., -1,0,1,2, or 3 cm). Surgical plan that includes a vaginal approach for apical or anterior prolapse repair. Able and willing to complete data collection per protocol, including written informed consent. Exclusion Criteria: Pregnancy or planning pregnancy in the first postoperative year. Any prior mid urethral sling. Currently participating in another interventional study for urinary incontinence. Untreated urinary tract infection (may be included after resolution). Overt symptoms of stress urinary incontinence as defined by a positive response to any of the following 3 PFDI items: Do you usually experience urine leakage related to coughing, sneezing, or laughing? Do you usually experience urine leakage related to physical exercise such as walking, running, aerobics, or tennis? Do you usually experience urine leakage related to lifting or bending over? Currently being treated for stress urinary incontinence with pessary/incontinence ring, pelvic floor muscle exercise or medication (duloxetine and imipramine, and alpha agonists).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John T Wei, MD
Organizational Affiliation
University of Michigan
Official's Role
Principal Investigator
Facility Information:
Facility Name
The University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233-7333
Country
United States
Facility Name
USCD Medical Center
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
Facility Name
Kaiser Permanente
City
San Diego
State/Province
California
ZIP/Postal Code
92120
Country
United States
Facility Name
Loyola University Medical Center
City
Maywood
State/Province
Illinois
ZIP/Postal Code
60153
Country
United States
Facility Name
Duke University
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
UT Southwestern
City
Dallas
State/Province
Texas
ZIP/Postal Code
35249
Country
United States
Facility Name
University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84132
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
22716974
Citation
Wei JT, Nygaard I, Richter HE, Nager CW, Barber MD, Kenton K, Amundsen CL, Schaffer J, Meikle SF, Spino C; Pelvic Floor Disorders Network. A midurethral sling to reduce incontinence after vaginal prolapse repair. N Engl J Med. 2012 Jun 21;366(25):2358-67. doi: 10.1056/NEJMoa1111967.
Results Reference
background
PubMed Identifier
32769645
Citation
Lukacz ES, Sridhar A, Chermansky CJ, Rahn DD, Harvie HS, Gantz MG, Varner RE, Korbly NB, Mazloomdoost D; Eunice Kennedy Shriver National Institute of Child Health and Human Development Pelvic Floor Disorders Network (PFDN). Sexual Activity and Dyspareunia 1 Year After Surgical Repair of Pelvic Organ Prolapse. Obstet Gynecol. 2020 Sep;136(3):492-500. doi: 10.1097/AOG.0000000000003992.
Results Reference
derived
Links:
URL
http://www.pfdnetwork.org
Description
Pelvic Floor Disorders Network

Learn more about this trial

Outcomes Following Vaginal Prolapse Repair and Mid Urethral Sling Trial

We'll reach out to this number within 24 hrs